EUCTR2007-004897-26-GB进行中（未招募）1 期
Memantine for the Long Term Management of Neuropsychiatric Symptoms in Alzheimer's disease - MAIN-AD - MAIN-AD
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Living: in a nursing or social care facilities.
- •Fulfil the NINCDS/ADRDA criteria for possible or probable Alzheimer's disease (AD).
- •Taking at least 0.5mg daily of haloperidol, 0.5mg daily of risperidone, 5mg daily of olanzapine or 25mg daily of quetiapine or another neuroleptic which in the opinion of the responsible clinician could be safely converted to one of these neuroleptics, for a minimum of 3 months prior to entry into the study.
- •If taking a cholinesterase inhibitor, prescribed for at least 6 months before the date of assessment, with a stable dose for at least 3 months.
- •Not taking anticonvulsants other than carbamazepine or sodium valproate. The use of either of these 2 agents is permissible if the dose has been stable for at least 4 weeks.
- •If taking any other psychotropic drugs (eg antidepressants, benzodiazepines, chlormethiazole), the dose has been stable for at least 4 weeks prior to randomization.
- •Not receiving treatment with memantine or have taken memantine in the past 6 weeks, and responsible clinician not considering treatment with memantine.
- •MMSE score =3 and =15.
- •Not taking any medications that are contra-indicated or not recommended in combination with memantine, as defined in the British National Formulary, including ketamine, dextromethorphan, amantidine.
- •Written informed consent provided by the participant’s next of kin or a legal representative.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Clinician responsible for care, or study clinician considers that the patient suffers from any physical condition (including marked extra-pyramidal disorder), which would make participation in the trial distressing or likely to increase suffering.
- •Patients with a systolic blood pressure whilst sitting greater than 180 mm/Hg or less than 90 mm/Hg, or a diastolic blood pressure whilst sitting greater than 100 mm/Hg or less than 50 mm/Hg at the screening visits or baseline.
- •Patients with a recent history (within 3 months of screening) or currently untreated B12 or folate deficiency.
- •Patients with a recent history (within 3 months) or untreated clinically significant hypothyroidism or hyperthyroidism (patients with thyroid disease may be included provided they are euthyroid and stable).
- •Severe aggression (=8) on item 3 of the NPI subscale, with aggression as the predominant symptom.
- •Patients with psychotic DSM IV TR Axis 1 disorder other than in the context of Alzheimer’s disease, including schizophrenia, schizoaffective disorder and bipolar disorder.
- •Participants known to have sensitivity to memantine, amantadine, rimantidine or lactose
- •A current diagnosis of primary neurodegenerative disorders other than Alzheimer’s disease such as, Huntington’s disease, Parkinson’s disease, etc.
- •Uncontrolled epilepsy.
- •Current evidence of delirium.
- •Moderate severe renal impairment, as measured by or equivalent to an estimated creatinine clearance of < 50 mL/min/1.73m2.
- •Severe hepatic impairment
- •Unable to swallow tablets or capsules.
- •Low probability of treatment compliance.
- •Currently taking memantine.
- •Previous evidence of lack of efficacy or tolerability to memantine.
- •Taking any of the following substances:
- •an investigational drug during the 4 weeks prior to randomization.
- •a drug known to cause major organ system toxicity during the 4 weeks prior to randomization.
- •started any new psychotropic during the 4 weeks prior to randomization. Participants who have been on a stable dose of psychotropic during the 4 weeks prior to randomization are still eligible.
- •memantine during the 6 weeks prior to randomization.
- •other N-methyl-D-aspartate (NMDA) antagonists: amantadine, ketamine, and dextromethorphan.
- •barbiturates and primidone.
- •baclofen and dantrolen.
- •dextrmethorphan.
- •antimuscarinics.
- •anticonvulsants other than sodium valproate or carbamazepine. These 2 agents are permissible if doses have been stable for at least 4 weeks.
研究者
相似试验
已完成
不适用
Memantine for the long term management of neuropsychiatric symptoms in Alzheimer's diseaseNervous System DiseasesAlzheimer's diseaseISRCTN68407918King's College London (UK)300
已完成
不适用
Systematic, longitudinal clinical neurological and observational imaging study of COVID-19.Post-/Long-COVIDU09.9Post COVID-19 condition, unspecifiedDRKS00028986niversitätsklinikum RWTH Aachen94
已完成
不适用
Memantine add on to treatment of refractory obssessive compulsive disorder: A double-blind clinical trialObsessive-compulsive disorderObsessive- Cumpulsive Disorder.IRCT138712141743N1Research Center for Behavioral Disorder and Substance Abuse, Hamadan University of Medical Sciences72
已完成
不适用
Differentiation of long-term neurological patients and implications for their care after hospital dischargePatients in neurorehabilitation Phase B, C, DDRKS00010947Klinik für Neurologie, Dr. Becker Rhein-Sieg-Klinik279
已完成
2 期
Memantine in the treatment of obsessive-compulsive disorderObsessive-compulsive disorderIRCT201106031556N22Tehran University of Medical Sciences40